---
layout: default
title: Access data
nav_order: 130
--- 
# Link to CT1.v1 IPD and interactive site 
[Note: please expect a short (30 second) delay while the site loads](https://labsyspharm.shinyapps.io/hmsclinical/)

Imputed IPD from ~150 trial publications in breast, colorectal, lung, and prostate cancer, which in aggregate comprise ~220,000 overall survival OS) or event-free survival events (e.g. progression free survival, PFS).

Citations: “Cancer patient survival can be parametrized to improve trial precision and reveal time-dependent therapeutic effects” by Deborah Plana, Geoffrey Fell, Brian M. Alexander, Adam C. Palmer, Peter K. Sorger. Nat Commun 13, 873 (2022). https://doi.org/10.1038/s41467-022-28410-9

Plana, D., Fell, G., Alexander, B. M., Palmer, A. C. & Sorger, P. K. Imputed individual participant data from oncology clinical trials. Synpase repository. https://doi.org/10.7303/SYN25813713 (2021).


# Link to CT2.v1 IPD 
[Donwload zip file with imputed IPD here](https://www.dropbox.com/sh/ourqmmh0l5uzmux/AADtmydISik-jXCmR0RDvfPLa?dl=1)

Imputed IPD from combination therapies with immune-checkpoint inhibitors across six cancer types including breast, gastric, head and neck, lung, melanoma, and renal.

Citation: “Predictable clinical benefits without evidence of synergy in trials of combination therapies with immune-checkpoint inhibitors” by Adam C. Palmer, Benjamin Izar , Haeun Hwangbo and Peter K. Sorger. Clin Cancer Res (2022) 28 (2): 368–377. https://doi.org/10.1158/1078-0432.CCR-21-2275
